Combination of Sulindac and Eflornithine Delays the Need for Lower Gastrointestinal Surgery in Patients with Familial Adenomatous Polyposis: Post Hoc Analysis of a Randomized Clinical Trial

FAP-310 Investigators

Research output: Contribution to journalArticlepeer-review

9 Scopus citations

Abstract

BACKGROUND: Colectomy and proctocolectomy are the initial standard of care for patients with familial adenomatous polyposis. Pharmacotherapy to prevent the progression of polyposis and surgeries in the lower GI tract would be beneficial to patients with this disease. OBJECTIVE: This analysis aimed to evaluate the impact of eflornithine-sulindac combination versus monotherapy in delaying time to disease progression in the lower GI tract of patients with familial adenomatous polyposis. DESIGN: This is a post hoc analysis of a randomized phase 3 trial. SETTING: This study was conducted in 21 hospitals in 7 countries treating patients with familial adenomatous polyposis. PATIENTS: Adults with familial adenomatous polyposis were randomly assigned 1:1:1 into 3 arms. INTERVENTIONS: Patients received either eflornithine (750 mg), sulindac (150 mg), or both once daily for up to 48 months. MAIN OUTCOME MEASURES: Efficacy was evaluated as the time from randomization to predefined primary disease progression end points. RESULTS: A total of 158 patients were included in the study. Disease progression was observed in 2 of 54 (3.7%), 9 of 53 (17.0%), and 10 of 51 (19.6%) patients with at least partial lower GI tract in the combination, sulindac, and eflornithine arms, corresponding to risk reductions of 80% (p = 0.02) and 83% (p = 0.01) between combination and sulindac or eflornithine. When endoscopic excision of adenomas ≥10 mm in size was censored, the need for major surgery was observed in 0 of 54, 7 of 53 (13.2%), and 8 of 51 (15.7%) patients in the combination, sulindac, and eflornithine arms, corresponding to risk reductions approaching 100% between combination and sulindac (p = 0.005) or combination and eflornithine (p = 0.003). LIMITATIONS: This was a post hoc analysis, the sample size was small, and there were fewer than expected events. CONCLUSIONS: Eflornithine-sulindac combination therapy was superior to either drug alone in delaying or preventing the need for lower GI tract surgery in patients with familial adenomatous polyposis.

Original languageEnglish
Pages (from-to)536-545
Number of pages10
JournalDiseases of the Colon and Rectum
Volume65
Issue number4
DOIs
StatePublished - Apr 1 2022

Keywords

  • Adenomatous polyposis coli
  • Eflornithine
  • Lower gastrointestinal tract
  • Sulindac
  • Treatment outcomes

Fingerprint

Dive into the research topics of 'Combination of Sulindac and Eflornithine Delays the Need for Lower Gastrointestinal Surgery in Patients with Familial Adenomatous Polyposis: Post Hoc Analysis of a Randomized Clinical Trial'. Together they form a unique fingerprint.

Cite this